Literature DB >> 185333

Demyelinative myelopathy in mice induced by the DA virus.

J R Lehrich, B G Arnason, F H Hochberg.   

Abstract

An attenuated tissue culture adapted strain of DA virus, an agent related to the Theiler murine encephalomyelitis viruses (TMEV), was used to induce a chronic myelopathy in mice. Spastic paraparesis first appeared 5 months after weanings were inoculated intracerebrally with the virus. None died as a direct result of the infection, and none improved once paretic. The major pathological change in these mice was demyelination of thoracic segments of spinal cord. No clinical illness or demyelinative pathology were detected during the first 4 months after inoculation. Encephalitic virus was present in brain and spinal cord as late as 10 months after inoculation. No neutralization antibody activity to DA virus was present in sera from 10 patients with amyotrophic lateral sclerosis, 10 with multiple sclerosis, or in 10 controls.

Entities:  

Mesh:

Year:  1976        PMID: 185333     DOI: 10.1016/0022-510x(76)90167-2

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  63 in total

1.  Axonal loss results in spinal cord atrophy, electrophysiological abnormalities and neurological deficits following demyelination in a chronic inflammatory model of multiple sclerosis.

Authors:  D B McGavern; P D Murray; C Rivera-Quiñones; J D Schmelzer; P A Low; M Rodriguez
Journal:  Brain       Date:  2000-03       Impact factor: 13.501

2.  Differences in avidity and epitope recognition of CD8(+) T cells infiltrating the central nervous systems of SJL/J mice infected with BeAn and DA strains of Theiler's murine encephalomyelitis virus.

Authors:  Bong-Su Kang; Michael A Lyman; Byung S Kim
Journal:  J Virol       Date:  2002-11       Impact factor: 5.103

3.  Quantitative ultrastructural analysis of a single spinal cord demyelinated lesion predicts total lesion load, axonal loss, and neurological dysfunction in a murine model of multiple sclerosis.

Authors:  S Sathornsumetee; D B McGavern; D R Ure; M Rodriguez
Journal:  Am J Pathol       Date:  2000-10       Impact factor: 4.307

4.  IgG subclass responses to Theiler's murine encephalomyelitis virus infection and immunization suggest a dominant role for Th1 cells in susceptible mouse strains.

Authors:  J D Peterson; C Waltenbaugh; S D Miller
Journal:  Immunology       Date:  1992-04       Impact factor: 7.397

5.  Heparan sulfate-independent infection attenuates high-neurovirulence GDVII virus-induced encephalitis.

Authors:  Honey V Reddi; A S Manoj Kumar; Aisha Y Kung; Patricia D Kallio; Brian P Schlitt; Howard L Lipton
Journal:  J Virol       Date:  2004-08       Impact factor: 5.103

6.  The 5' noncoding sequences from a less virulent Theiler's virus dramatically attenuate GDVII neurovirulence.

Authors:  H L Lipton; M Calenoff; P Bandyopadhyay; S D Miller; M C Dal Canto; S Gerety; K Jensen
Journal:  J Virol       Date:  1991-08       Impact factor: 5.103

7.  The relationship between viral RNA, myelin-specific mRNAs, and demyelination in central nervous system disease during Theiler's virus infection.

Authors:  M Yamada; A Zurbriggen; R S Fujinami
Journal:  Am J Pathol       Date:  1990-12       Impact factor: 4.307

8.  Intravenous immunoglobulin therapy in multiple sclerosis: progress from remyelination in the Theiler's virus model to a randomised, double-blind, placebo-controlled clinical trial.

Authors:  J H Noseworthy; P C O'Brien; B G van Engelen; M Rodriguez
Journal:  J Neurol Neurosurg Psychiatry       Date:  1994-11       Impact factor: 10.154

9.  Phylogenetic analysis of the species Theilovirus: emerging murine and human pathogens.

Authors:  Zhiguo Liang; A S Manoj Kumar; Morris S Jones; Nick J Knowles; Howard L Lipton
Journal:  J Virol       Date:  2008-09-24       Impact factor: 5.103

10.  Biochemical analysis of DA strain of Theiler's murine encephalomyelitis virus obtained directly from acutely infected mouse brain.

Authors:  R P Roos; P J Whitelaw
Journal:  Infect Immun       Date:  1984-06       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.